Datapoint: Gilead Scores Expanded Hep B Nod for Vemlidy

The FDA last week expanded Gilead Sciences’ chronic hepatitis B virus (HBV) drug Vemlidy’s label to include pediatric patients 12 and older with compensated liver disease. The drug was first approved in 2016. As of November 2022, 91% of insured lives have covered or better access to Vemlidy, with 25% of lives having preferred access to the drug without utilization management restrictions.

SOURCE: MMIT Analytics, as of 11/7/22

0

0

0 Comments

0

0

• Datapoint